Background and Aims: Cigarette smoking causes persistent airway inflammation and is considered to be a major cause of chronic obstructive pulmonary disease (COPD). The activation of Phosphoinositide 3-kinase (PI3K)/Akt pathway is known to be important in COPD pathogenesis. Phosphatase and Tensin Homolog Deleted from Chromosome 10 (PTEN) is a negative regulator of PI3K/Akt pathway and reported to be associated with COPD. However, the level and the role of PTEN in COPD subjects remain unclear.
mRNA expression was significantly correlated with the parameters of obstructive impairment, such as %FEV1 (r = 0.26, P < 0.01), FEV1/FVC (r = 0.2, P = 0.04), and %DLco (r = 0.34, P = 0.0011). There was no significant difference in PI3Kdelta mRNA levels between each group.
Conclusion:
The decrease of PTEN expression was correlated with obstructive impairment of COPD. PTEN might be a possible therapeutic target for COPD. Results: In total, 17 patients (12 COPD, 5 asthma) received Foster ® MDI and 15 patients (11 COPD, 4 asthma) treated with Seretide ® MDI. There were no differences between two groups in baseline demographics, PaO 2 / FiO 2 ratio, comorbidity, and APACHE II scores. Patients with AECOPD and severe asthma showed significant improvement of airway resistance after Foster ® inhalation (-2.48 AE 3.40 cmH20/L•S-1, P = 0.009). This improvement was not observed in patients with Seretide ® (−0.40 AE 1.94 cmH20/ L•S-1, P = 0.426). There was no significant change in compliance after treatment in both groups. Clinically, there were no differences between two groups in steroid use, ventilator days, ICU days, and in hospital survival. For EIT patterns, there were no differences in regularity and specific patterns regarding delta-EELI and spatial or temporal differences of ventilation distribution between two groups. We further examined the level of end-expiratory flow (EEF), which related to air trapping and intrinsic PEEP in mechanical ventilated patients. We observed a significant correlation between global EEF and the sum of regional EEF (correlation coefficient r = 0.65, P < 0.00001). However, the improvement of regional EEF after ICS/LABA inhalation was significant in asthma (P < 0.005) but not in COPD patients.
Conclusion: These findings indicate that Foster
® had better immediate effect on reducing airway resistance. Regional EEF could provide diagnostic information to monitor the disease progress during treatment. Here, we founded small molecule C that is able to reduce CS-and PPEmediated inflammation, ROS or apoptosis through cAMP-related pathway. We would like to show the therapeutic effect of the small molecule C in COPD experimental model in vivo and in vitro.
Methods: For animal models of COPD, mice were injected PPE (5 U/100 g) for 2 weeks, and then small molecule C (0.5 mg/kg) was administered to mice by daily i.p. injection. The murine alveolar type II epithelial cells (MLE-12) were exposed by 0.6% cigarette smoke extract (CSE) for 24 h, and 0.1-3 μM small molecule C was pre-treated for 24 h before the exposure with CSE in vitro.
Results: Small molecule C inhibited CSE-mediated apoptosis, inflammation and oxidative stress. CSE increased MAPKs pathway signalling in MLE-12 cells, while small molecule C attenuated activation of MAPKs signalling. In mice, PPE-induced emphysematous pathology was reduced by treatment of small molecule C. Moreover, small molecule C increased cAMP activity in the lung tissues.
Conclusion:
We have shown the therapeutic ability of small molecule C in COPD experimental models in vivo and in vitro. 
